Science plus technology to address challenges in determining the efficacy of neuroprotective/neurorestorative therapies-Reference-Cited by-同舟云学术

Science plus technology to address challenges in determining the efficacy of neuroprotective/neurorestorative therapies

Published:2021-01-24 Issue: Volume: Page:
ISSN:
Container-title:Exploration of Neuroprotective Therapy
language:en
Short-container-title:Explor Neuroprot Ther

Author:

Franco Rafael¹

Affiliation:

1. School of Chemistry, Universitat de Barcelona, Barcelona, 08028 Barcelona, Spain 2Network Center, Neurodegenerative Diseases (CiberNed), Spanish National Healt.Institute Carlos III. 28031 Madrid, Spain

Publisher

Open Exploration Publishing

Reference50 articles.

1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. [DOI] [PubMed]

2. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124:901–5. [DOI] [PubMed]

3. Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson’s disease. Rev Neurol (Paris). 2016;172:14–26. [DOI] [PubMed]

4. Silva MVF, Loures CDMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:33. [DOI] [PubMed] [PMC]

5. Ye Q, Bai F, Zhang Z. Shared genetic risk factors for late-life depression and Alzheimer’s disease. J Alzheimer’s Dis. 2016;52:1–15. [DOI] [PubMed]

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on the Molecular Mediators of Oxidative Stress and Antioxidant Strategies in the Context of Neuroprotection and Neurolongevity: An Extensive Review;Oxidative Medicine and Cellular Longevity;2022-08-26